Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition
Novo Holdings investment in Availity
We advised Availity on the investment
Aligos Therapeutics $83.6 million follow-on offering
We advised the underwriters on the stock offering
Zylox-Tonbridge Medical Technology HK$2.56 billion IPO
We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing
HUTCHMED HK$4.17 billion IPO and primary listing
The shares are listed on the Hong Kong Stock Exchange
GH Research $184 million IPO
We advised GH Research on the IPO and Nasdaq Listing
Theravance Biopharma $100.5 million follow-on offering
We advised the underwriters on the equity offering
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Cyteir Therapeutics $133.2 million IPO
We advised the underwriters on the IPO and Nasdaq listing